Russian oil tycoon to build pharma plant in Minsk, Belarus
The Belarusian government has signed an investment agreement with MSP-oil, an oil company owned by Russian tycoon Vladimir Bryntsalov, for a pharmaceutical plant to be built in Minsk, Belarus, the local BelaPAN newspaper reported this week.
Around three quarters of the Russian pharmaceutical market is supplied by imports as the domestic production of innovative pharmaceuticals is negligible.
The new plant, which is expected to manufacture substitutes for imported medicines, will be built by Belarusian-Russian pharmaceutical company Ferein, which is 75% owned by Mr Bryntsalov and 25% to the Belarusian government.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze